| dbpprop:abstract
|
- Carisoprodol is a centrally-acting skeletal muscle relaxant whose safety and efficacy is well established. Although reports from Norway have shown that carisoprodol has abuse potential as a prodrug of meprobamate and/or potentiator of hydrocodone, dihydrocodeine, codeine and similar drugs, it continues to be prescribed in North America, alongside orphenadrine and cyclobenzaprine. In Europe, doctors favor cyclobenzaprine. In the United Kingdom, benzodiazepines are preferred instead. All of the above plus chlorzoxazone are used in Canada. The opioid-potentiator effect of carisoprodol and other skeletal muscle relaxants is also harnessed in clinical settings. Carisoprodol is a colorless, crystalline powder, having a mild characteristic odor and a bitter taste. It is slightly soluble in water and freely soluble in alcohol, chloroform and acetone. Its solubility is practically independent of pH. Carisoprodol is marketed in the United States under the brand name Soma, and in the United Kingdom and other countries under the brand names Sanoma and Carisoma. Carisoprodol is especially useful against various types of pain (whether or not related to muscle spasm) because of its analgesic-sparing (potentiating) effect on opioid analgesics. Carisoprodol is available by itself or mixed with aspirin and in one preparation (Soma Compound With Codeine) along with codeine and caffeine as well As of November 2007 Carisoprodol (Somadril, Somadril comp. ) has been taken off the market in Sweden due to problems with dependence and side effects. The agency overseeing pharmaceuticals has considered other drugs used with the same indications as carisoprodol to have the same or better effects without the risks of the drug.. In the EU, the European Medicines Agency has issued a release recommending that member states suspend marketing authorization for this product in the treatment of acute (not chronic) back pain. As of August 2009, carisoprodol is considered to be a schedule CIV by the states of Alabama, Arizona, Arkansas, Florida, Georgia, Hawaii, Indiana, Kentucky, Louisiana, Massachusetts, Minnesota, New Mexico, Nevada, Oklahoma, Oregon and Texas (scheduled using the states new controlled substance program which requires physicians to obtain, and include, a state "DPS" number as well as a DEA number on all Scheduled drugs) and Washington State (not verified, WA still using DEA scheduling). It is a schedule CIII in West Virginia. The rest of the United States, excluding the above named states, falls under the DEA scheduling for the drug, which considers carisoprodol a non-scheduled chemical, meaning that carisoprodol is considered a general prescription medication by the federal government of the United States, with oversight provided solely by the U.S. Food and Drug Administration (FDA).
- Carisoprodol ist ein zentral wirkendes Muskelrelaxans, dessen aktiver Metabolit Meprobamat ist.
- Karisoprodol er et muskelavslappende legemiddel, som brukes i behandlingen av muskel- og skjelettsmerter. I Norge markedsføres preparatet under produktnavnet Somadril. Legemiddelverket har besluttet at Somadril skal være A-resept-pliktig fra 1. mai 2006, og vil bli avregistrert 1. mai 2007. Begrunnelsen for dette er at det er påvist omfattende misbruk av preparatet, og at det er dårlig dokumentasjon for preparatets nytteverdi i behandlingen av smerter
- O carisoprodol é um fármaco utilizado pela medicina como relaxante muscular. É também usado como intensificador do efeito de certos opiáceos, tais como codeína, di-hidrocodeína, tramadol e outros.
- Somadril är ett muskelrelaxerande medel med smärtstillande verkan. Aktiv substans är karisoprodol, vilket är beroendeframkallande. Det finns ingen modern dokumentation för karisoprodol och det är sällan man påbörjar en ny behandling med detta nuförtiden. Däremot är det många som står på preparatet sedan länge och inte kan sluta. Försäljningen av läkemedlet Somadril och Somadril Comp upphör i Sverige 1 juni 2008, men kan fortsättningsvis skrivas ut av läkare med licens från läkemedelsverket. Se även läkemedelsberoende.
|
| rdfs:comment
|
- Carisoprodol is a centrally-acting skeletal muscle relaxant whose safety and efficacy is well established. Although reports from Norway have shown that carisoprodol has abuse potential as a prodrug of meprobamate and/or potentiator of hydrocodone, dihydrocodeine, codeine and similar drugs, it continues to be prescribed in North America, alongside orphenadrine and cyclobenzaprine. In Europe, doctors favor cyclobenzaprine. In the United Kingdom, benzodiazepines are preferred instead.
- Carisoprodol ist ein zentral wirkendes Muskelrelaxans, dessen aktiver Metabolit Meprobamat ist.
- Karisoprodol er et muskelavslappende legemiddel, som brukes i behandlingen av muskel- og skjelettsmerter. I Norge markedsføres preparatet under produktnavnet Somadril. Legemiddelverket har besluttet at Somadril skal være A-resept-pliktig fra 1. mai 2006, og vil bli avregistrert 1. mai 2007. Begrunnelsen for dette er at det er påvist omfattende misbruk av preparatet, og at det er dårlig dokumentasjon for preparatets nytteverdi i behandlingen av smerter
- O carisoprodol é um fármaco utilizado pela medicina como relaxante muscular. É também usado como intensificador do efeito de certos opiáceos, tais como codeína, di-hidrocodeína, tramadol e outros.
- Somadril är ett muskelrelaxerande medel med smärtstillande verkan. Aktiv substans är karisoprodol, vilket är beroendeframkallande. Det finns ingen modern dokumentation för karisoprodol och det är sällan man påbörjar en ny behandling med detta nuförtiden. Däremot är det många som står på preparatet sedan länge och inte kan sluta.
|
![[RDF Data]](/statics/sw-cube.png)
